Last10K.com

Aeolus Pharmaceuticals, Inc. (AOLS) SEC Filing 10-K Annual report for the fiscal year ending Wednesday, September 30, 2009

Aeolus Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1261734 Ticker: AOLS
Exhibit 99.1
Aeolus Pharmaceuticals, Inc. Logo
Contact:
    John L. McManus
    President and Chief Executive Officer
    (949) 481-9825

Aeolus Pharmaceuticals Announces Fiscal Year 2009 Financial Results
 
Mission Viejo, California, December 28, 2009 -- Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today financial results for the three months and twelve months ended September 30, 2009.  The Company reported a net loss of $746,000, or $0.02 per share, for the three months ended September 30, 2009 compared to a loss of $1,055,000, or $0.03 per share, for the three months ended September 30, 2008.  Results for the three months ended September 30, 2008 included licensing income of $175,000, a related collaboration charge of $413,000 for a milestone payment due under a license agreement and a non-cash charge of $118,000 as a result of the re-pricing of certain warrants.
 
The Company reported a net loss of $2,296,000, or $0.07 per share, for the fiscal year ended September 30, 2009, compared to a loss of $2,973,000, or $0.09 per share, for the fiscal year ended September 30, 2008.
 
“Fiscal 2009 was a year of major progress for Aeolus in the development of AEOL 10150 as a medical countermeasure”, stated John L. McManus, President and Chief Executive Officer.  “In addition to reporting significant efficacy in studies of the compound as a countermeasure for exposure to radiation, sulfur mustard gas and chlorine gas, we have continued to secure funding from the National Institutes for Health for further development of our lead compound and from investors for the operation of the Company.  We look forward to the completion of additional, key studies of the compound and our second compound AEOL 11207, and remain committed to leveraging our financial resources through our partnerships with the federal government and our academic research partners.”
 
Research and development expenses decreased in fiscal 2009 when compared to fiscal 2008.  The lower level of R&D expenses during the current period reflects a lower amount of manufacturing and research expenses.  During fiscal 2008, we were in the process of manufacturing small quantities of our drug candidates to support our development program whereas during fiscal 2009 we had no manufacturing underway and were only running stability studies on existing drug supplies.  Research expenses also declined during the current year as more of the Company’s research programs were funded by external grants during fiscal 2009.  The Company currently has five studies under way for its lead compound, AEOL 10150:
 
·  
as a medical countermeasure against the effects of acute radiation syndrome (“ARS”) in the lungs,
·  
as a medical countermeasure against the effects of acute radiation syndrome in the gastro-intestinal tract,
·  
as a medical countermeasure against the effects of sulfur mustard gas on the lungs
·  
as a medical countermeasure against the effects of sulfur mustard gas on the skin, and
·  
as a medical countermeasure against the effects of chlorine gas.
 
The following information was filed by Aeolus Pharmaceuticals, Inc. (AOLS) on Monday, December 28, 2009 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Aeolus Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aeolus Pharmaceuticals, Inc..

Continue

Assess how Aeolus Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aeolus Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2009 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools
Ticker: AOLS
CIK: 1261734
Form Type: 10-K Annual Report
Accession Number: 0001261734-09-000039
Submitted to the SEC: Mon Dec 28 2009 10:58:40 AM EST
Accepted by the SEC: Mon Dec 28 2009
Period: Wednesday, September 30, 2009
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/aols/0001261734-09-000039.htm